19 research outputs found

    Human T-lymphotropic virus type-1 p30 alters cell cycle G2 regulation of T lymphocytes to enhance cell survival

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Human T-lymphotropic virus type-1 (HTLV-1) causes adult T-cell leukemia/lymphoma and is linked to a number of lymphocyte-mediated disorders. HTLV-1 contains both regulatory and accessory genes in four pX open reading frames. pX ORF-II encodes two proteins, p13 and p30, whose roles are still being defined in the virus life cycle and in HTLV-1 virus-host cell interactions. Proviral clones of HTLV-1 with pX ORF-II mutations diminish the ability of the virus to maintain viral loads <it>in vivo</it>. p30 expressed exogenously differentially modulates CREB and Tax-responsive element-mediated transcription through its interaction with CREB-binding protein/p300 and while acting as a repressor of many genes including Tax, in part by blocking tax/rex RNA nuclear export, selectively enhances key gene pathways involved in T-cell signaling/activation.</p> <p>Results</p> <p>Herein, we analyzed the role of p30 in cell cycle regulation. Jurkat T-cells transduced with a p30 expressing lentivirus vector accumulated in the G2-M phase of cell cycle. We then analyzed key proteins involved in G2-M checkpoint activation. p30 expression in Jurkat T-cells resulted in an increase in phosphorylation at serine 216 of nuclear cell division cycle 25C (Cdc25C), had enhanced checkpoint kinase 1 (Chk1) serine 345 phosphorylation, reduced expression of polo-like kinase 1 (PLK1), diminished phosphorylation of PLK1 at tyrosine 210 and reduced phosphorylation of Cdc25C at serine 198. Finally, primary human lymphocyte derived cell lines immortalized by a HTLV-1 proviral clone defective in p30 expression were more susceptible to camptothecin induced apoptosis. Collectively these data are consistent with a cell survival role of p30 against genotoxic insults to HTLV-1 infected lymphocytes.</p> <p>Conclusion</p> <p>Collectively, our data are the first to indicate that HTLV-1 p30 expression results in activation of the G2-M cell cycle checkpoint, events that would promote early viral spread and T-cell survival.</p

    Adoption of Inhana Rational Farming (IRF) Technology as an Organic Package of Practice towards Improvement of Nutrient Use Efficiency of Camellia Sinensis through Energization of Plant Physiological Functioning

    Get PDF
    The effectivity of Inhana Rational Farming (IRF) Technology towards energization of plant physiological functioning was evaluated in comparison to other organic packages of Practice under FAO-CFC-TBI Project at Maud Tea Estate, Dibrugarh, Assam, India during 2008 to 2013. The study area lies in 27.26. N latitude and 95.12 E longitude covering a total area of 154.58 ha area with level to nearly level landscape. The experiment was laid down as per randomized block design (RBD) with 8 treatments replicated 3 times. The treatments included available two organic methods viz. Biodynamic Farming (BD) and Inhana Rational Farming (IRF) (developed by Dr. P. Das Biswas, Founder, Inhana Biosciences, Kolkata) as well as organic inputs viz. vermicompost, bio-fertilizers, bio-pesticides, herbal formulations which are used in organic tea gardens in India on large scale. The organic inputs selected for evaluation were combined to form different ‘Packages of Practice’ based on scientific rationale. The different packages were : Biodynamic (BD) with Biodynamic compost, Conventional Organic Practice with Indigenous compost @ 13.5 ton/ha (CO), Inhana Rational Farming Tech-nology with 8 ton Novcom Compost (IRF-2), Inhana Rational Farming Technology with 5.1 ton Novcom Compost (IRF-4), Vermi-compost @ 9.4 ton/ha + Conventional Organic Practice (VCO), Vermicompost @ 9.4 ton/ha + Microbial Formulations for both soil and plant management (VMI), Vermicompost @ 9.4 ton/ha + Microbial Formulations for only plant management i.e. Bio-pesticides+ Bio-growth promoter (VMIP). Agronomic Efficiency (NUE), which among other factors depends upon the nutrient uptake and utilization efficiency of plant or con-versely the state of plant physiology was assessed to score the different organic packages as per N expensed for unit crop production. Highest NUE was obtained under IRF packages followed by VMI, VMIP and VCO. The highest crop yield along with high NUE under IRF-2 indicated an effective management approach towards activation of plant physiology. But the most significant finding was that there was a considerable enhancement of nutrient use efficiency under the treatment plots which received total package of practice(ie. both plant and soil management) in comparison to the plots which received only the soil management part of the same package of practice (12.35 to 93.77 % increase). The results indicated towards a definitive role of organic plant management w.r.t. enhancement of the plant physiological functioning. While the agronomic efficiency was found highest in both soil management as well as complete package under IRF technology but also the percent change in agronomic efficiency (total package vs. only soil management part of the same package) was highest in case of IRF package of practice. This indicated positive impact of IRF plant management programme towards plant physiological functioning leading to higher crop response

    Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Bladder cancer is a significant healthcare problem in the United States of America with a high recurrence rate. Early detection of bladder cancer is essential for removing the tumor with preservation of the bladder, avoiding metastasis and hence improving prognosis and long-term survival. The objective of this study was to analyze the presence of DEK protein in voided urine of bladder cancer patients as a urine-based bladder cancer diagnostic test.</p> <p>Methods</p> <p>We examined the expression of DEK protein by western blot in 38 paired transitional cell carcinoma (TCC) bladder tumor tissues and adjacent normal tissue. The presence of DEK protein in voided urine was analyzed by western blot in 42 urine samples collected from patients with active TCC, other malignant urogenital disease and healthy individuals.</p> <p>Results</p> <p>The DEK protein is expressed in 33 of 38 bladder tumor tissues with no expression in adjacent normal tissue. Based on our sample size, DEK protein is expressed in 100% of tumors of low malignant potential, 92% of tumors of low grade and in 71% of tumors of high grade. Next, we analyzed 42 urine samples from patients with active TCC, other malignant urogenital disease, non-malignant urogenital disease and healthy individuals for DEK protein expression by western blot analysis. We are the first to show that the DEK protein is present in the urine of bladder cancer patients. Approximately 84% of TCC patient urine specimens were positive for urine DEK.</p> <p>Conclusion</p> <p>Based on our pilot study of 38 bladder tumor tissue and 42 urine samples from patients with active TCC, other malignant urogenital disease, non-malignant urogenital disease and healthy individuals; DEK protein is expressed in bladder tumor tissue and voided urine of bladder cancer patients. The presence of DEK protein in voided urine is potentially a suitable biomarker for bladder cancer and that the screening for the presence of DEK protein in urine can be explored as a noninvasive diagnostic test for bladder cancer.</p
    corecore